B. Riley Wealth Advisors Inc. Has $1.10 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

B. Riley Wealth Advisors Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,919 shares of the biopharmaceutical company's stock after selling 8,087 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in Gilead Sciences were worth $1,101,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter worth approximately $31,000. Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in Gilead Sciences during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on GILD. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the transaction, the chief financial officer now owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,929 shares of company stock worth $5,644,780 in the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.76 during mid-day trading on Friday, hitting $110.35. 11,912,582 shares of the stock traded hands, compared to its average volume of 7,741,965. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market cap of $137.27 billion, a price-to-earnings ratio of 298.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company's 50-day simple moving average is $105.49 and its 200-day simple moving average is $100.78. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.